CELL & GENE: An Analysis Of The Gene Therapy Viral Vector Landscape

Over the last five years, multiple gene therapies have been approved by regulatory agencies, and a bolus of late-stage pipeline assets are approaching the market. As the first gene therapies began to post early wins, several challenges have emerged. With the growing evidence of delivery as the Achilles heel of gene therapy, research and funding into the development of improved gene delivery vehicles has skyrocketed. Kyle O’Neil and Brendan Wang of Back Bay Life Science Advisors discuss the landscape of the viral vector sector in Cell & Gene, here.